Drug reference

Abacavir

Antiretroviral

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

5 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 5 →

LeflunomideSevereDatabaseDDInter
LomitapideSevereDatabaseDDInter
MipomersenSevereDatabaseDDInter
PexidartinibSevereDatabaseDDInter

Mechanism

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI). It functions as part of a backbone regimen in combination antiretroviral therapy for HIV infection.

Indications

HIV infectionHIV infection in pregnancyHIV-1 infection in combination with other antiretroviral agentsHIV infection (in combination regimens)

Dosing

Adult: Lansoprazole 30 mg. Figure 7–12. Effect of CYP2C19 genotype on proton pump inhibitor (PPI) pharmacokinetics (AUC), gastric pH, and ulcer cure rates.

Pharmacokinetics

Half-life

0.8–1.5

Bioavailability

83%

Protein binding

50%

Metabolism

>80% (dehydrogenation; glucuronidation)

Side effects

Common

feverabdominal painGI complaintsmild maculopapular rashmalaisefatiguecoughpharyngitisdyspneamusculoskeletal complaintsheadacheparesthesias

Serious

hypersensitivity syndrome (potentially fatal)
hypersensitivity reactions (rashes, fever, abdominal pain, bowel upset, flu-like respiratory and constitutional symptoms) in 2–5% adults. Fatalities have occurred upon re-challenge, so it must be promptly stopped if a reaction occurs and never re-administered.
lypodystrophy (least likely)